Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers
about
sameAs
Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.Levetiracetam in the Treatment of Epileptic Seizures After Liver TransplantationPharmacokinetics in special populations.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations.Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects.Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration.Levetiracetam pharmacokinetics in Japanese subjects with renal impairment.Clinical pharmacology of levetiracetam for the treatment of epilepsy.Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient.Brivaracetam disposition in mild to severe hepatic impairment.Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.In Situ Metabolism of Levetiracetam in Blood of Patients with Epilepsy
P2860
Q34469479-6B7DFBC8-FB70-4896-A7FE-D6FEB808084EQ36255864-C20DBD1C-6BAF-43F7-B492-16F8C05BC965Q37550561-B5EA291F-F67E-48C1-95C9-643144ED1EDEQ38152329-1462DDD2-D909-4F6C-B7DB-06AD5F6D0958Q38586750-421E04BE-E2E3-4189-83B3-E20081511076Q38764753-C71B11CD-540A-4D50-94DC-F610065CCDE8Q41125106-C831682B-87FC-46D6-ADC1-58BF59AF849DQ42289811-AD622D62-21FF-4B8B-967B-62EEE7290417Q42688026-CEBC1A91-CB0E-4B03-A20F-7A1B53DE1E5BQ42723600-FB4F6055-4613-46BC-A13D-0619213BF221Q43980511-44C8AA87-A51D-4E8E-AF49-2BB1FC4A26BCQ44231616-CAD735D5-5E7C-43A7-B9A9-FB031243B189Q44942290-581BB3C7-59B1-488D-B434-66C11AAD1820Q46984909-D0B5D831-6C97-46C5-9C12-AEE3AE3E61E5Q48281323-D1A4F2EB-F736-42D5-B4E0-7CE64FF79601Q53118030-A1BF60FA-6486-4B9C-A2FC-65B032D82C6BQ58449880-A89EFE06-653A-466F-9EF4-BE12050B39A9
P2860
Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@ast
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@en
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@nl
type
label
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@ast
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@en
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@nl
prefLabel
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@ast
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@en
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@nl
P2093
P1476
Pharmacokinetics and metabolis ...... c agent, in healthy volunteers
@en
P2093
Colin Young
Eugène Baltes
Jean-Marie Nicolas
Margherita Strolin Benedetti
Rhys Whomsley
P2888
P304
P356
10.1007/S00228-003-0655-6
P407
P577
2003-11-01T00:00:00Z
P6179
1034487862